SCHEDULE: Vanguard Group Reports 0% Cytokinetics Stake

The Vanguard Group has reported a 0% beneficial ownership in Cytokinetics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 11 to Schedule 13G regarding its beneficial ownership of Cytokinetics Inc. Common Stock.
• As of the event date of March 13, 2026, The Vanguard Group's aggregate beneficial ownership in Cytokinetics Inc. is 0.00%.
• This change is attributed to an internal realignment within The Vanguard Group on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis), and The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over these securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Cytokinetics Inc., as the change in beneficial ownership by The Vanguard Group is due to an internal organizational realignment rather than a specific investment decision related to the issuer's performance or prospects.

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that institutional ownership changes, especially from major asset managers like The Vanguard Group, can sometimes signal shifts in investment strategy or portfolio rebalancing. However, in this case, the change is explicitly due to an internal organizational realignment rather than a change in investment thesis regarding Cytokinetics Inc.

Stakeholder Impact

• Shareholders of Cytokinetics Inc. should be aware of the change in reporting structure for a significant institutional investor, though the underlying investment by Vanguard's subsidiaries may still exist, just reported differently.

Key Dates

Keywords

Cytokinetics Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, SEC Filing, Investment Management